Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Ribose-5-P isomerase deficiency is an extremely rare, hereditary, disorder of pentose phosphate metabolism characterized by progressive leukoencephalopathy and a highly increased ribitol and D-arabitol levels in the brain and body fluids. Clinical presentation includes psychomotor delay, epilepsy, and childhood-onset slow neurological regression with ataxia, spasticity, optic atrophy and sensorimotor neuropathy.
Features include always present findings: Incoordination, Elevated circulating ribitol concentration, and Global developmental delay. 24 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 9 | Seizure, Polyneuropathy, Ataxia |
RPIA function has not been fully characterized.
Ribose-5-P isomerase deficiency is associated with mutations in the RPIA gene on chromosome 2.
Genetic testing for RPIA is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for ribose-5-P isomerase deficiency has been reported in the published literature.
Phenotype severity distribution: 3 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for ribose-5-P isomerase deficiency.
5 publications have been identified in PubMed for ribose-5-P isomerase deficiency. Research spans Basic Science / Preclinical (60%), Diagnostic / Biomarker (20%), and Review / Meta-Analysis (20%).
Qiao J (2025). [PMID: 39859324](https://pubmed.ncbi.nlm.nih.gov/39859324/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Seregina TA (2025). [PMID: 41294827](https://pubmed.ncbi.nlm.nih.gov/41294827/). *Cells*. [Basic Science / Preclinical]
Hallier M (2024). [PMID: 38591898](https://pubmed.ncbi.nlm.nih.gov/38591898/). *mSphere*. [Basic Science / Preclinical]
Cardoso AS (2024). [PMID: 39061492](https://pubmed.ncbi.nlm.nih.gov/39061492/). *Animals : an open access journal from MDPI*. [Diagnostic / Biomarker]
Bhattacharjee P (2024). [PMID: 38778156](https://pubmed.ncbi.nlm.nih.gov/38778156/). *The EMBO journal*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 2:43 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
6 |
Increased CSF D-threitol concentration, Decreased level of erythritol in urine, Increased CSF xylitol concentration |
Eyes | 2 | Nystagmus, Damage to the optic nerve (optic atrophy) |
Muscles | 1 | Damage to the optic nerve (optic atrophy) |